Scientific publications - VCS Foundation - VCS Foundation

Understanding the proportion of cervical cancers attributable to HPV

Julia ML Brotherton, Alison C Budd, Marion Saville.
Medical Journal of Australia, 7th January 2020

Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening

Hannah Shilling, Gerald Murray, Julia M.L. Brotherton, David Hawkes, Marion Saville, Terri Sivertsen, Ian Chambers, Jennifer Roberts, Annabelle Farnsworth, Suzanne M. Garland, Jane S. Hocking, John Kaldor, Rebecca Guy, Steph Atchison, Anna-Maria Costa, Monica Molano, Dorothy A. Machalek.
Vaccine 38 (2020) 1186-1193

Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination

Julia Brotherton.
Papillomavirus Research Volume 8, December 2019

Lessons from the renewal of the National Cervical Screening Program in Australia.

Smith M, Hammond I, Saville M.
Public Health Res Pract. 2019;29(2):e2921914.

Australia on track to be the first country to achieve cancer elimination

K.Canfell, M.Hall, K.Simms, M.Smith, M.Saville.
HPV World No 65

Evaluation of p16/Ki-67 dual stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer

Toliman. PJ, Phillips. S, O'Neil, T, Tan. G, Brotherton. JML, Saville. M, Kaldor. JM, Vallely. AJ, Tabrizi. SN.
Clinical Microbiology and Infection

Management and long‐term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study

Tan J. H, Malloy M. J, Thangamani R, Gertig D, Drennan K. T, Wrede C. D, Saville M, Quinn M.
(2019) Aust N Z J Obstet Gynaecol.

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programs: updated systematic review and meta-analysis.,

Drolet M, Bénard E, Pérez N, Brisson M , Brotherton JML.
The Lancet Volume 394, Issue 10197. P497-509

Human papillomavirus vaccination coverage and course completion rates among Aboriginal and Torres Strait Islander adolescents.

Brotherton JML, , Winch K, Chappell GA, Banks C, Meijer D, Nicholls S, Webby R, Whop LJ.
Med J Aust. 2019

Impact of HPV vaccination: Achievements and future challenges

J.M. Brotherton.
Papillomavirus Research (2019)

The remarkable impact of bivalent HPV vaccine in Scotland

Brotherton Julia M L..
BMJ 2019; 365 :l1375

Evaluation of self-collected vaginal specimens for the detection of high-risk HPV infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.

Toliman P, Kaldor J, Badman SG, Phillips S, Tan G, Brotherton JM, Saville M, Vallely A, Tabrizi S.
(2018) Clinical Microbiology and Infection. doi: 10.1016/j.cmi.2018.05.025.

Recurrent disease after treatment for cervical pre-cancer: determining if prophylactic HPV vaccination could play a role in prevention of secondary lesions.

Velentzis LS, Brotherton JML, Canfell K.
Climacteric 2019

Immunisation coverage annual report, 2015.

Hull BP, Hendry AJ, Dey A, Beard FH, Brotherton JML, McIntyre P.
Commun Dis Intell (2018) 2019;43

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Velentzis L S., Smith M A., Simms KT., Lew JB, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Brotherton JML., Skinner R, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland SM., Guy R, Hammond I, Grogan P, Arbyn M, Castle PE., Saville M, Armstrong BK., Canfell K.
(2019) Gynecologic Oncology 152(3): 465-471. doi: 10.1016/j.ygyno.2018.12.019

Response to “Cancer elimination thresholds: one size does not fit all.”

Hall M, Smith MA, Brotherton JML, Simms KT, Canfell K.
Lancet Public Health. 2019;4:e47

Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?

Farhana Sultana, Karen Winch, Marion Saville, Julia M.L. Brotherton.
International Journal of Cancer 2019.

Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact.

Julia ML. Brotherton, David Hawkes, Farhana Sultana, Michael J. Malloy, Dorothy A. Machalek, Megan A. Smith, Suzanne M. Garland, Marion Saville.
Vaccine 2018.

The projected timeframe until cervical cancer elimination in Australia: a modelling study.

Hall M. T., Simms K. T., Lew J. B., Smith M. A., Brotherton J. M., Saville M., Frazer I. H., Canfell K..
(2019) Lancet Public Health 4(1): e19-e27. 10.1016/s2468-2667(18)30183-x

Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea

Toliman PJ, Kaldor JM, Gabuzzi J, Silim S, Kumbia A, Kombuk B, Kombati Z, Munnull G, Guy R, , Vallely L, Kelly-Hanku AM, Wand H, Ryan C, Tan G, Brotherton JML, Saville M, Mola GD, Garland SM, Tabrizi SN, Vallely A.
Papillomavirus Research 2018;6:70-76.

Clinical validation of the cobas HPV test on the cobas 6800 system for the purpose of cervical screening.

Marion Saville, Farhana Sultana, Michael J. Malloy, Louiza S. Velentzis, Michael Caruana, Ellen L. O. Ip, Marco H. T. Keung, Karen Canfell, Julia M. L. Brotherton, David Hawkes.
J Clin Microbiol. 2018 Nov 21. pii: JCM.01239-18.

Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993-2016

Li M, Roder D, Whop LJ, Diaz A, Baade PD, Brotherton JML, Canfell K, Cunningham J, Garvey G, Moore SP, O’Connell DL, Valery PC, Condon JC.
J Med Screen. 2018 Nov 12:969141318810719

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Patel C., Brotherton J. M., Pillsbury A., Jayasinghe S., Donovan B., Macartney K., Marshall H..
(2018) Euro Surveill 23(41). doi:10.2807/1560-7917.es.2018.23.41.1700737

Should Cervical Cancer Screening be Performed Before the Age of 25 Years?

Moscicki A. B., Perkins R. B., Saville M., Brotherton J. M. L..
(2018) J Low Genit Tract Dis 22(4): 348-351. doi: 10.1097/LGT.0000000000000434.

Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs

Smith MA, Brotherton JML, Hammond I, Anderson L, Simms K, Saville M, Canfell K.
Journal of the American Society of Cytopathology 2018;7(6):336-8

HPV testing as part of the renewed National Cervical Screening Program

Hawkes D..
Australian Journal of General Practice. AJGP Vol. 47, No. 7, July 2018

There are no old roads to new directions.

Roeske L. .
Australian Journal of General Practice. AJGP Vol. 47, No. 7, July 2018

Human papillomavirus vaccination update: nonavalent vaccine and the two-dose schedule. Australian Journal of General Practice

Brotherton JML .
AJGP Vol. 47, No. 7, July 2018

Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study

Skye McGregor, Dina Saulo, Julia Brotherton, Bette Liu, Samuel Phillips, S. Rachel Skinner, Michele Luey, Lisa Oliver, Mary Stewart, Sepehr N. Tabrizi, Suzanne Garland, John M. Kaldor.
Vaccine 36 (2018) 4311–4316

“Lest we forget” as we move forward with cervical screening

Marion Saville, Orla McNally.
Aust N Z J Obstet Gynaecol 2018; 58: 265–266

Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program

Suzanne M. Garland, Alyssa M. Cornall, Julia M.L. Brotherton, John D. Wark, Michael J. Malloy, Sepehr N. Tabrizi, on behalf of the VACCINE study group.
Vaccine 36 (2018) 3221–3230

Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland

Paramita Dasgupta, Lisa J. Whop, Abbey Diaz, Susanna M. Cramb, Suzanne P. Moore, Julia M.L. Brotherton, Joan Cunningham, Patricia C. Valery, Dorota Gertig, Gail Garvey, John R. Condon, Dianne L. O’Connell, Karen Canfell, Peter D. Baad.
Geographical Research 2018

Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012)

Abbey Diaz, Peter D. Baade, Patricia C. Valery, Lisa J. Whop, Suzanne P. Moore, Joan Cunningham, Gail Garvey, Julia M. L. Brotherton, Dianne L. O'Connell, Karen Canfell, Diana Sarfati, David Roder, Elizabeth Buckley, John R. Condon.
PLOS One 13(5): e0196764. May 8, 2018

Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination

Dorothy A. Machalek, Suzanne M. Garland, Julia M. L. Brotherton, Deborah Bateson, Kathleen McNamee, Mary Stewart, S. Rachel Skinner, Bette Liu, Alyssa M. Cornall, John M. Kaldor, Sepehr N. Tabrizi.
The Journal of Infectious Diseases Volume 217, Issue 10, 23 April 2018, Pages 1590–1600

Reply to San Giorgi and Dikkers

Daniel Novakovic, Julia M. L. Brotherton.
The Journal of Infectious Diseases. Vol 217, Issue 9, 11 April 2018

Safety of Human Papillomavirus Vaccines: An Updated Review

Phillips Anastasia, Patel Cyra, Pillsbury Alexis, Brotherton Julia, Macartney Kristine.
Drug Safety April 2018, Volume 41, Issue 4, pp 329–346

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25 to 69 years living in Australia

Karen Canfell, Marion Saville, Michael Caruana, Val Gebski, Jessica Darlington-Brown, Julia ML Brotherton, Stella Heley, Philip E. Castle.
BMJ Open 2018 8: doi: 10.1136/bmjopen-2017-016700

IPVS Statement Moving towards Elimination of Cervical Cancer as a Public Health Problem

SM Garland, A Giuliano, JML Brotherton, AB Moscicki, M Stanley, AM Kaufmann, N Bhatla, R Sankaranarayanan, JM Palefsky, S de Sanjose, on behalf of IPVS.
Papillomavirus Research Available online 27 Feb 2018

Self-collection for under-screened women as part of the renewed National Cervical Screening Program: A Pilot Study

Saville M, Hawkes D, Mclachlan E, Anderson S, Arabena K. .
Current Oncology, Curr Oncol. 2018 Feb;25(1):e17-e26

Completing the cervical screening pathway: An Australian pilot of HPV self-collection for under-screened and never-screened women

McLachlan E, Anderson S, Saville M, Hawkes D, Arabena K..
Current Oncology, Curr Oncol. 2018 Feb;25(1):e27-e32

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.

Hall MT, Simms Kate, Lew Jie-Bin, Smith Megan, Saville A Marion, Canfell Karen.
(2018) PLOS One 13(2).

Population based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage

Julia M.L. Brotherton, Paul N. Bloem.
Best Practice & Research Clinical Obstetrics and Gynaecology 47 (2018) 42e58

A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program

Daniel Novakovic, Alan T L Cheng, Yvonne Zurynski, Robert Booy, Paul J Walker, Robert Berkowitz, Henley Harrison, Robert Black, Christopher Perry, Shyan Vijayasekaran, David Wabnitz, Hannah Burns, Sepehr N Tabrizi, Suzanne M Garland, Elizabeth Elliott, Julia M L Brotherton.
J Infect Dis. 2018 Jan 4;217(2):208-212.

Sisters doing it for themselves A safe and acceptable self-collection model for cervical cancer screening

Sandy Anderson – Ballarat and District Aboriginal Co-operative (BADAC), Associate Professor Marion Saville – Victorian Cytology Service Ltd (VCS), Dr David Hawkes – Victorian Cytology Service Ltd (VCS), Professor Kerry Arabena – The Centre for Health Equity and the Indigenous Health Equity, Elizabeth McLachlan – The University of Melbourne, Ruvimbo Bako – Department of Health and Human Services, Rachael Andersen – Department of Health and Human Services.
Poster - 6th Annual NHMRC Symposium on Research Translation co-hosted with the Lowitja Institute

A new era for cervical screening in Australia: Watch this space

Hammond I., Canfell K., Saville M..
Aust N Z J Obstet Gynaecol, 57: 499–501. doi:10.1111/ajo.12669

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination Results of the Compass pilot randomised trial

Karen Canfell, Michael Caruana, Val Gebski, Jessica Darlington-Brown, Stella Heley, Julia Brotherton, Dorota Gertig, Chloe J. Jennett, Annabelle Farnsworth, Jeffrey Tan, C. David Wrede, Philip E. Castle, Marion Saville.
PLOS Medicine 19 September, 2017

Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination

Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland SM.
Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.

Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.

Alexis J. Pillsbury, Helen E. Quinn, TaNisha D. Evans, Peter B. McIntyre, Julia M. L. Brotherton..
Clin Infect Dis 2017, 3rd July 2017

Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.

Jie-Bin Lew, D James B St John, Xiang-Ming Xu, Marjolein J E Greuter, Michael Caruana, Dayna R Cenin, Emily He, Marion Saville, Paul Grogan, Veerle M H Coupé, Karen Canfell.
Lancet Public Health 2017; 2: e331–40, Published Online, June 26, 2017

Addressing Confusion about the Risks and Benefits of Co-Testing versus Human Papillomavirus Tests for Cervical Cancer

Grace Tan, David Hawkes.
Acta Cytologica May 5, 2017 DOI:10.1159/000472244

Cost-effectiveness estimates: the need for complete reporting

Jie-Bin Lew, Kate T Simms, Megan A Smith, Marion Saville, Ian Hammond, Karen Canfell.
The Lancet Vol 2 May 2017

HPV vaccine coverage is increasing in Australia

Julia ML Brotherton, Karen L Winch, Lisette Bicknell, Genevieve Chappell, Marion Saville.
Medical Journal of Australia MJA 206 (6) 3 April 2017 doi: 10.5694/mja16.00958

Annual Immunisation Coverage Report 2014

Hull BP, Hendry AJ, Dey A, Beard FH, Brotherton JM, McIntyre PB.
BP Hull et al. Commun Dis Intell Q Rep 41 (1), E68-E90. 2017 Mar 31.

Response to “Vaccine-related serious adverse events might have been under-recognised in the pivotal HPV vaccine randomized trial”

David Hawkes.
Clin Rheumatol. 2017 Mar 25. DOI: http://dx.doi.org/10.1007/s10067-017-3609-6

Response to: HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women withpre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study

D. Hawkes, W. Wilkinson & R. A. Dunlop.
Journal of Internal Medicine 2017 doi:10.1111/joim.12602

Self collection Pilot Project improving access to cervical screening for underscreened women

Developed by the University of Melbourne and Victorian Cytology Service Ltd for the Victorian Department of Health and Human Services.
Evaluation Report February 2017

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated

Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I, Canfell K..
Lancet Public Health. 2017 Feb;2(2):e96-e107. Epub 2017 Feb 7.

Time to clinical investigation after a high-grade abnormal Pap test for indigenous and non-indigenous women in Queensland, 2000–2011.

Whop LJ, Baade P, Brotherton JML, Canfell K, Cunningham J, Gertig DM, Lokuge K , Garvey G , Moore SP, Diaz A, O’Connell DL, Valery PC, Roder D, Condon JR..
Med J Aust 2017; 206 (2): 73-77. doi:10.5694/mja16.00255

Optimal Management Strategies for Primary HPV Testing for Cervical Screening – Cost-

Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K.
PLoS One. 2017 Jan 17;12(1):e0163509.

Progress in HPV vaccination in low-and lower-middle- income countries

D. Scott LaMontagne, Paul J.N. Bloem, Julia M.L. Brotherton, Katherine E. Gallagher, Ousseynou Badiane, Cathy Ndiaye.
Int J Gynecol Obstet 2017; 138 (Suppl. 1): 7–14

IPVS Policy statement on safety of HPV vaccines

Garland SM, Stanley M, Brotherton J, Mosckiki A-G, Bhatla N, Kaufmann AM, Sankaranarayanan R, Palefsky J.
Papillomavirus Research 2016; 2: 9-10

Monitoring the impact of HPV vaccine in males – considerations and challenges

Brotherton JML, Giuliano A, Markowitz L, Dunne E, Ogilvie G.
Papillomavirus Research 2016; 2: 106-111

The population impact of HPV vaccination programmes on HPV infection with the non-vaccine HPV genotypes: a systematic review and meta-analysis.

Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL. .
Emerging Infectious Diseases.2016;22(10):1732-1740.

Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch up

Staples C, Butler M, Nguyen J, Durrheim DN, Cashman P, Brotherton JML.
Sexual Health 2016. Published online 29 August 2016

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

Julia M.L. Brotherton, Mark Jit, Patti E. Gravitt, Marc Brisson, Aim ee R. Kreimer, Sara I. Pai, Carole Fakhry, Joseph Monsoneg , Silvia Franceschi.
Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22

Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia

Farhana Sultana, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Robyn Mullins, Julia M.L. Brotherton, C. David Wrede, Stella Heley, Marion Saville, Dorota M. Gertig.
International Journal of Cancer Volume 139, Issue 2, pages 281–290, 15 July 2016

Primary Prevention of HPV through Vaccination: Update on Current Global Status

Brotherton JML, Zuber PLF, Bloem PJN.
Curr Obst Gynecol Reports 2016. Published online 7 July 2016.

The Role of Pejorative Search Terms and Professional Antivaccine Advocates on Search Engine Results for Human Papillomavirus Vaccine

Tracey McDermott, David Hawkes Ph.D., Joanne Benhamu, R.N..
Journal of Adolescent Health 58 (2016) 691e694

Changes to the cervical cancer screening program in Australia

Karen Canfell, Marion Saville, Ian Hammond, Lara Roeske.
Medicine Today, May 2016, 17(5), 59-82

The First Comprehensive Report on Indigenous Australian Women’s Inequalities in Cervical Screening: A Retrospective Registry Cohort Study in Queensland, Australia (2000-2011)

Lisa J. Whop, Gail Garvey, Peter Baade, Joan Cunningham, Kamalini Lokuge, Julia M. L. Brotherton, Patricia C. Valery, Dianne L. O'Connell, Karen Canfell, Abbey Diaz, David Roder, Dorota Gertig, Suzanne P. Moore, John R. Condon.
Cancer: Volume 122, Issue 10, pages 1560–1569, May 15, 2016

Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use

Megan A. Smith, Dorota Gertig, Michaela Hall, Kate Simms, Jie-Bin Lew, Michael Malloy, Marion Saville, Karen Canfell..
BMC Health Services Research (2016) 16:147

Juvenile recurrent respiratory papillomatosis: 10 year audit and Australian prevalance estimates

Novakovic D, Cheng A, Baguley K, Walker P, Harrison H, Soma M, Malloy M, Brotherton JML.
The Laryngoscope 2016. 2016 Apr 14.

Cervical Abnormalities Are More Common among Indigenous than Othe Australian Women: A Retrospective Record-Linkage Study, 2000-2011

Lisa J. Whop, Peter Baade, Gail Garvey, Joan Cunningham, Julia M. L. Brotherton, Kamalini Lokuge, Patricia C. Valery, Dianne L. O’Connell, Karen Canfell, Abbey Diaz, David Roder, Dorota M. Gertig, Suzanne P. Moore, John R. Condon.
PLOS ONE, April 11, 2016

Immunisation coverage annual report, 2013

Hull BP, Dey A, Beard FH, Menzies RI, Brotherton JM, McIntyre PD.
Commun Dis Intell Q Rep. 2016 March 31;40(1): E146-69

HPV vaccine impact in Australian women: ready for an HPV-based screening program

Julia ML Brotherton, Dorota M Gertig, Cathryn May, Genevieve Chappell, Marion Saville.
MJA 204 (5) 21 March 2016

Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project.

Whop LJ, Diaz A, Baade P, Garvey G, Cunningham J, Brotherton JML, Canfell K, Valery PC, O'Connell D, Taylor C, Moore SP, Condon JR..
BMJ Open 2016;6:e009540

Human papillomavirus vaccination and primary ovarian insufficiency: an association based on ideology rather than evidence

David Hawkes, Jim Buttery.
Curr Opin Obstet Gynecol: 2016

HPV Vaccination: Current Global Status

Julia M.L Brotherton, Paul J.N Bloem.
Current Obstetrics and Gynecology Reports 2015

HPV vaccines: so much learnt, so many more lessons to come

Julia M.L Brotherton.
The Lancet Oncology

Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia

Julia M.L. Brotherton, Michael Malloy, Alison C. Budd, Marion Saville, Kelly T. Drennan, Dorota M. Gertig.
Papillomavirus Research Volume 1, December 2015, Pages 59–73

Cervical cancer prevention in Australia: Planning for the future

A. Marion Saville.
Cancer Cytopathology, Vol 124, 4, 235-240

Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-participation

Brotherton JML, Piers LS, Vaughan L.
Sexual Health 2015

Women’s experience with home-based self- sampling for human papillomavirus testing

Farhana Sultana, Robyn Mullins, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Stella Heley, C. David Wrede, Julia M. L. Brotherton, Marion Saville, Dorota M. Gertig.
BMC Cancer (2015) 15:849

The acceptability and cost of a home-based chlamydia retesting strategy: findings from the REACT randomised controlled trial

Smith K., Kaldor J., Hocking J., Jamil M., McNulty A., Read P., Bradshaw C., Chen M., Fairley C., Wand H., Worthington K., Blake S., Knight V., Rawlinson W., Saville M., Tabrizi S., Garland S., Donovan B., Guy R..
BMC Public Health.2016, 16:83 DOI: 10.1186/s12889-016-2727-4

Human Papillomavirus (HPV) Vaccination Safety Assessment: The Methods Matter

Julia M. L. Brotherton, Kristine K Macartney, Etsuko Miyagi, Jim P. Buttery.
Intern Med 54: 2531, 2015

HPV.edu study protocol: a cluster randomized controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents

S. Rachel Skinner, Cristyn Davies, Spring Cooper, Tanya Stoney, Helen Marshall, Jane Jones, Joanne Collins, Heidi Hutton, Adriana Parrella, Gregory Zimet, David G. Regan, Patti Whyte, Julia M. L. Brotherton, Peter Richmond, Kirsten McCaffrey, Suzanne M. Garland, Julie Leask, Melissa Kang, Annette Braunack-Mayer, John Kaldor, Kevin McGeechan.
BMC Public Health 2015

Current status of human papillomavirus vaccination

JML Brotherton, GS Ogilvie.
Curr Opin Oncol 2015:27(5):399-404

HPV prophylactic vaccines: lessons learned from 10 years experience

Brotherton JML.
Future Virology, Vol. 10, No. 8 , Pages 999-1009

A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing.

Farhana Sultana, Dorota M. Gertig, C. David Wrede, Dallas R. English, Julie A. Simpson, Kelly T. Drennan, Julia M.L. Brotherton, Gillian Phillips, Stella Heley, Philip E. Castle, Marion Saville.
Journal of Clinical Virology 2015 69 (2015) 210–213

Measuring HPV vaccination coverage in Australia:comparing two alternative population-based denominators

Bianca Barbaro, Julia M.L. Brotherton.
Australian and New Zealand Journal of Public Health Aust NZ J Public Health. 2015; Online; 2015

Could one dose of bivalent HPV vaccine prevent cervical cancer?

Julia ML Brotherton.
Lancet Oncol 2015:16(7):739-40

Human papillomavirus prevalence to age 60 years among Australian women prevaccination

Julia M. L. Brotherton, John R. Condon, Peter B. McIntyre, Sepehr N. Tabrizi, Michael Malloy, Suzanne M. Garland, and on behalf of the WHINURS study group .
Sexual Health, June 2015

Human Papillomavirus control. How are we going with vaccination coverage seven years in

Brotherton JML, Chappell G, Brosi J, Bicknell L, Winch K, Barbaro B, Saville M.
Poster presentation Communicable Disease Control Conference - June 2015

Women’s views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting.

Sultana F, Mullins R, Murphy M, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM.
Sexual Health 2015: 12(4): 279-286

Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer—Could a Schistosomiasis Vaccine be the Third?

Michael H. Hsieh, Julia M. L. Brotherton, Afzal A. Siddiqui.
PLOS Neglected Tropical Diseases, May 2015

The effect of making a ‘third dose assumption’ on HPV coverage estimates

Brotherton JML, Winch K..
Australian and New Zealand Journal of Public Health: Volume 39, Issue 2, pages 193–194, April 2015

Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia

Julia M. L. Brotherton, A. Marion Saville, Cathryn L. May, Genevieve Chappell, Dorota M. Gertig.
Cancer Causes and Control: Published On-Line 25th March 2015

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

Mélanie Drolet PhD, Élodie Bénard BSc, Marie-Claude Boily PhD, Hammad Ali PhD, Louise Baandrup MD, Heidi Bauer MD, Simon Beddows PhD, Jacques Brisson DSc, Julia M L Brotherton BMed, Teresa Cummings BA, Basil Donovan MD, Christopher K Fairley PhD, Elaine W Flagg PhD, Anne M Johnson MD, Jessica A Kahn MD, Kimberley Kavanagh PhD, Susanne K Kjaer MD, Erich V Kliewer PhD, Philippe Lemieux-Mellouki MSc, Lauri Markowitz MD, Aminata Mboup MSc, David Mesher MSc, Linda Niccolai PhD, Jeannie Oliphant FAChSHM, Kevin G Pollock PhD, Kate Soldan PhD, Pam Sonnenberg PhD, Sepehr N Tabrizi PhD, Clare Tanton PhD, Dr Marc Brisson PhD.
Lancet Infect Dis 2015: Published Online March 3, 2015

Asking About Human Papillomavirus Vaccination and the usefulness of Registry Validation: A Study of Young Women Recruited Using Facebook

Bharathy Gunasekaran, Yasmin Jayasinghe, Julia M.L. Brotherton, Yeshe Fenner, Elya E. Moore, John D. Wark, Ashley Fletcher, Sepehr N. Tabrizi, Suzanne M. Garland.
Vaccine, 33, no. 6., pp. 749-832, 4 Feb 2015.

Two or three doses of human papillomavirus vaccine?

Brotherton JML.
BMJ 2015;350:g7778 (Published 07 January 2015)

Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia

Julia ML Brotherton, Michael R Batchelor, Michelle O Bradley, Scott A Brown, Simone M Duncombe, Dennis Meijer, Lauren E Tracey, Maureen Watson, Rosalind J Webby.
Communicable Disease Intelligence 2015 Vol 39, No2

HPV Vaccination: Current Global Status

Brotherton JML, Bloem PJN.
Curr Obstet Gynecol Rep 2015

Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program

Sarah L. Osborne, Sepehr N. Tabrizi, Julia M.L. Brotherton, Alyssa M. Cornall, John D. Wark, C. David Wrede, Yasmin Jayasinghe, Dorota M. Gertig, Marian K. Pitts, Suzanne M. Garland, on behalf of the VACCINE Study group..
Vaccine, 33, 2015, pp. 201-208.

What you need to know about: Human Papillomavirus Vaccination

Brotherton JML.
British Journal of Hospital Medicine 2014; 75(11): C165-C168

Human Papillomavirus Vaccination

Julia ML Brotherton.
British Journal of Hospital Medicine, November 2014, 75, no.11.

Immunisation Coverage, 2012

Brynley P Hull, Aditi Dey, Rob I Menzies, Julia M Brotherton, Peter B McIntyre.
Communicable Diseases Intelligence, 38, no. 3, September 2014, pp. E208-31.

Cervical screening rates for women vaccinated against human papillomavirus

Alison C Budd, Julia M L Brotherton, Dorota M Gertig, Theresa Chau, Kelly T Drennan, Marion Saville.
Med J Aust 2014; 201 (5): 279-282

High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: A cohort study with 10 years of follow-up.

Sultana F, English D, Simpson J, Canfell K, Gertig D, Saville M.
International Journal of Cancer, 2014, 135 (5), 1 Sept 2014, 1213-19

Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: What do you need to know? [Letter]

Julia ML Brotherton, C David H Wrede.
ANZJOG, 2014, 54 (4): 393-396. Article first published online: 13 AUG 2014.

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

Sepehr N Tabrizi, Julia M L Brotherton, John M Kaldor, S Rachel Skinner, Bette Liu, Deborah Bateson, Kathleen McNamee, Maria Garefalakis, Samuel Phillips, Eleanor Cummins, Michael Malloy, Suzanne M Garland.
Lancet Infect Dis, 2014, published online August 6, 2014.

HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program

Sepehr N. Tabrizi, Julia M.L. Brotherton, Matthew P. Stevens, John R. Condon, Peter McIntyre, David Smith, Suzanne M. Garland, on behalf of the WHINURS group.
Journal of Clinical Virology, 2014, 60 (3), July 2014, 250-56.

Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?

Bianca Barbaro, Julia M.L. Brotherton..
Australian and New Zealand Journal of Public Health, 2014, 38 (4), published online 24 June 2014.

Human papillomavirus vaccination: Where are we now?

Julia Brotherton.
Journal of Paediatrics and Child Health, 2014, 50 (8), published online 9 June 2014.

How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions

Callegari ET, Tabrizi SN, Pyman J, Saville M, Cornall AM, Brotherton JML, Garland SM..
Vaccine, 2014, 32, 4082-4088. Published online 22 May 2014

Rationale and design of REACT: a randomised controlled trial assessing the effectiveness of home-collection to increase chlamydia retesting and detect repeat positive tests

Kirsty S Smith, Jane S Hocking, Marcus Chen, Christopher K Fairley, Anna McNulty, Phillip Read, Catriona S Bradshaw, Sepehr N Tabrizi, Handan Wand, Marion Saville, William Rawlinson, Suzanne M Garland, Basil Donovan, John M Kaldor, Rebecca Guy.
BMC Infectious Diseases, 2014,14:223.

Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never-and under-screened women in Australia

Sultana F, English DR, Simpson JA, Brotherton JML, Drennan K, Mullins R, Heley S, Wrede CD, Saville M, Gertig DM.
BMC Cancer, 2014. 14:207. DOI:10.1186/1471-2407-14-207

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: a case-control study nested within a population-based screening program in Australia

Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB, Whiteman DC.
BMJ, 2014, 348:g1458, doi: 10.1136/bmj.g.1458. Published on-line 4 Mar 2014.

Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011.

Liu B, Donovan B, Brotherton JML, Saville M, Kaldor JM..
Sex Transm Infect, 2014, 25 February. doi:10.1136/sextrans-2013-051307

Barriers to better three-dose coverage with HPV vaccination in school-based programs.

Watson M, D'Onise K, Lynch J, Brotherton JML.
Aust N Z J Public Health, 2014, 38(1):91-92.

Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey.

Brotherton JML, Liu B, Donovan B, Kaldor JM, Saville M.
Vaccine, 2014, 32 (5): 592-597, 23 Jan 2014.

Immunisation coverage annual report, 2011

Hull BP, Dey A, Menzies RI, Brotherton JML, McIntyre PB.
Commun Dis Intell Q Rep. 2013 Dec 31;37(4):E291-312

Human papillomavirus vaccine national catch up program: insights into under notification

Laemmele-Ruff I, Barbaro B, Brotherton JML.
Aust Fam Physician, 2013, 42(12): 880-884.

Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.

Brotherton JML, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, Pitcher HC, Scully MM, Molchanoff L..
Med J Aust, 2013, 199 (9) :614-617, doi: 10.5694/mja13.10272

Safety of the quadrivalent human papillomavirus vaccine [editorial].

Brotherton JML..
BMJ, 2013, 347:f5631

Utility of reports and routine correspondence from the National HPV Vaccination Program Register.

Brotherton JML, Batchelor M, Winch K..
Med J Aust, 2013, 199 (7): 463.

HPV testing in the National Cervical Screening Program, When is it recommended?

Heley S..
Australian Family Physician Vol. 42, No. 7, July 2013: 463:466.

The Impact of Vaccination and what it means for Cytology Screening

Gertig D, Brotherton J, Saville M.
HPV Today, 2013, July.

Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)

Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM.
BMC Cancer 2013 June 19;13:296.

Safety of human papillomavirus vaccines: a review

Macartney KK, Chiu C, Georgousakis M, Brotherton JM.
Drug Safety 2013 Jun;36(6):393-412.

Adapting the Australian system: is an organized screening program feasible in Malaysia? – an overview of cervical cancer screening in both countries

Rashid RM, Dahlui M, Mohamed M, Gertig D.
Asian Pac J Cancer Prev 2013;14(3):2141-6.

Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study.

Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM.
BMC Medicine, 2013, 11:227, doi:10.1186/1741-7015-11-227

Why a special issue on anal cancer and what is in it?

Fairley CK, Brotherton JM, Hillman R, Grulich AE..
Sexual Health 2012 Dec;9(6):501-3.

Time for a strategic research response to anal cancer

Grulich AE, Hillman R, Brotherton JM, Fairley CK.
Sexual Health 2012 Dec;9(6):628-31.

Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.

Brotherton JM, Mullins RM..
Cancer Epidemiol, 2012, Jun; 36(3): 298-302. Epub 2011 Dec 8.

Expenditure and resource utilisation for cervical screening in Australia

Lew JB, Howard K, Gertig D, Smith M, Clements M, Nickson C, Shi JF, Dyer S, Lord S, Creighton P, Kang YJ, Tan J, Canfell K.
BMC Health Serv Res 2012 Dec 5;12:446.

Fall in human papillomavirus prevalence following a national vaccination program

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM.
J Infect Dis 2012 Dec 1;206(11): 1645-51.

Human papillomavirus vaccine introduction – the first five years

Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM.
Vaccine 2012 Nov 20:30 Suppl 5:F139-48.

Fall in human papillomavirus prevalance following a national vaccination program

Tabrizi SN, Brotherton JML, Kaldor JM Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM.
Journal of Infectious Diseases. 2012;206(11):1645-51

Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study

Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K..
Lancet Infect Dis., 2012, 12 (8), Aug 2012, 627-34.

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J.
Int J Cancer 2012 Nov 1;131(9):1969-82. EPub 2 July 2012.

Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria

Barbaro B, Brotherton JML, Gertig D..
Med J Aust, 2012, Apr 16; 196 (7): 445.

Human papillomavirus and head and neck cancers: emerging trends and improving survival [letter to the editor].

Brotherton JML, Stein A, Conway L, Grulich A, Law M, Hocking J..
Aust NZ J Pub Health, 2012, Apr; 36(2): 195-6.

Genital HPV types in Australia [letter].

Brotherton JML, Garland S, Donovan B.
Lancet Infect Dis., 2012, Feb;12(2):102-3.

Does human papillomavirus type 16 or 18 prevalence in CIN3 lesions vary by age? An important issue for post vaccination surveillance.

Brotherton JML, Tabrizi SN, Garland SM..
Future Micobiol., 2012, Feb; 7(2), 193-9.

Mobile phones are a viable option for surveying young Australian women: a comparison of two telephone survey methods.

Liu B, Brotherton JML, Shellard D, Donovan B, Saville M, Kaldor JM..
BMC Medical Research Methodology, 2011, 11: 159, doi:10.1186/1471-2288-11-159

The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.

Smith MA, Lew JB, Walker RJ, Brotherton JML, Nickson C, Canfell K..
Vaccine, 2011, 29 (48), 8 Nov 2011, 9112-22

Adolescent and young adult HPV vaccination in Australia: achievements and challenges.

Garland SM, Skinner SR, Brotherton JML.
Prev Med, 2011, Oct 1; 53 Suppl 1: S29-35.

Primary prophylactic HPV vaccination programs: future perspective on global impact.

Brotherton JML, Gertig DM.
Expert Rev Anti Infect Ther, Aug 2011, 9 (8): 627-39.

Early effect of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study

Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM.
The Lancet 2011; 377:2085-2092

Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study

Brotherton JML, Fridman M, May C, Chappell G, Saville AM, Gertig DM.
The Lancet, 2011, 377(9783), 11 Jun 2011, 2085-92.

Catching up with the catch- up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.

Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M..
Commun Dis Intell, Jun 2011, 35(2): 197-201.

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

Gertig DM, Brotherton JML, Saville M.
Sexual Health, 2011, 8: 171-178.

Human papillomavirus prevalence amongst Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program.

Garland SM*, Brotherton JML*, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN, [* joint first authors].
BMC Med., 2011, 9(1): 104.

Trends in anal cancer in Australia, 1982-2005

Jin F , Stein AN, Conway EL, Regan D, Law M, Brotherton JML, Hocking J , Grulich A..
Vaccine, 2011, 29 (12), 9 Mar 2011, 2322-27.

Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers

Hocking J, Stein A, Conway L, Grulich A, Law M, Brotherton JML..
British Journal of Cancer, 2011, 104, 886-891. Published online 1 Feb 2011.

Approaches to Monitoring Biological Outcomes for HPV Vaccination: Challenges of Early Adopter Countries

Wong CA, Saraiya M, Hariri S, Eckert L, Howlett RI, Markowitz LE, Brotherton JML.
Vaccine, 2011, 29 (5): 878-885.

“I just signed”: Factors influencing decision making for school-based HPV vaccination.

Cooper Robbins SC, Bernard D, McCaffery K, Brotherton JML, Skinner SR..
Health Psychology, 2010, 29 (6): 618-25.

Australian HPV Surveillance [letter]

Brotherton JML, Kaldor JM, McIntyre PB..
Vaccine, 2010, 28 (47), 7453-7454.

Human papillomavirus genotype detection from archival papanicolaou-stained cervical tests.

Tabrizi S, Taylor N, McCullough MJ, Phillips G, Wark J, Gertig D, Petersen R, Saville M, Garland S..
Cancer Cytopathology, 2010, 118(6). Published online 12 Oct 2010.

Sexual Health

.
Special Issue: Human Papillomavirus Sexual Health Sept 2010, Vol 7, Issue 3

Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia’s role.

Garland SM, Brotherton JML, Fairley CK, Gertig DM, Saville M.
Sexual Health, 2010, 7 (3): 227-229.

Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy

Brotherton JML, Kaldor JM, Garland SM..
Sexual Health, 2010, 7(3),310-19.

Estimating the incidence of, and treatment patterns for, juvenile onset recurrent respiratory papillomatosis in Australia pre vaccination: a pilot study.

Novakovic D, Cope D, Cheng ALT, Brotherton JML..
Sexual Health, 2010, 7 (3), 19 Aug 2010, 253-61.

Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.

Brotherton JML, Fairley CK, Garland SM, Gertig DM, Saville M.
Sexual Health, 2010, 7 (3): 397-398.

National survey of the general practitioner’s experience of delivering the National Human Papillomavirus Vaccination Program.

Brotherton JML, Leask J, Jackson C, McCaffery K, Trevena LJ..
Sexual Health, 2010, 7:291-298.

“Is cancer contagious?”: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV Vaccination.

Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Skinner SR..
Vaccine, 2010, 28, issue 19, 26 April 2010, 3398-3408

Australia needs a national centre for disease control [letter].

Brotherton JML, Kaldor JM, Saville M..
Med J Aust, 2010, 193 (10): 623-624.

Abnormal Pap tests after the HPV vaccine.

Heley S, Brotherton J..
Aust Family Physician, 2009, 38 (12): 977-9, Dec 2009.

Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.

Agorastos T, Chatzigeorgiou K, Brotherton JML, Garland SM..
Vaccine, 2009, 27 (52), 9 Dec 09, 7270-7281.

The incidence of genital warts in Australian women prior to the national vaccination program.

Brotherton JML, Heywood A, Heley S.
Sexual Health, 2009, 6 (3):178-184

Estimating coverage of the National HPV Vaccination Program: where are we at? [letter] .

Brotherton JML, Mullins R..
Med J Aust, 2009, 191(3):188

Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk Factors, Epidemiology and Prevention.

Garland Suzanne, Brotherton Julia, Skinner Richard, Pitts Marian, Saville Marion, Mola Glen, Jones Ronald.
Vaccine, 2008, 26; Suppl 12, M80-M88, 9 Aug 2008.

Outstanding Problems – Glandular Lesions.

Saville Marion, Bloomfield Penny.
Cancer Forum, 2008, July 2008; 32 (2).

Temporal Associations with Declining Trichomonas vaginalis Diagnosis Rates Among Women in the State of Victoria Australia, 1947 to 2005.

Marrone John, Fairley Christopher, Saville Marion.
Sexually Transmitted Diseases, Jun 2008, 35 (6), 572-576